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AdipogenesisMicrorchidia (MORC) family CW-type zinc ﬁnger 2 (MORC2) has been shown to be involved in several nuclear
processes, including transcription modulation and DNA damage repair. However, its cytosolic function remains
largely unknown. Here, we report an interaction between MORC2 and adenosine triphosphate (ATP)-citrate
lyase (ACLY), an enzyme that catalyzes the formation of acetyl-coA and plays a central role in lipogenesis,
cholesterogenesis, and histone acetylation. Furthermore, we demonstrate thatMORC2 promotes ACLY activation
in the cytosol of lipogenic breast cancer cells and plays an essential role in lipogenesis, adipogenesis and
differentiation of 3T3-L1 preadipocytic cells. Consistently, the expression ofMORC2 is induced during the process
of 3T3-L1 adipogenic differentiation andmousemammary gland development at a stage of increased lipogenesis.
This observation was accompanied by a high ACLY activity. Together, these results demonstrate a cytosolic
function of MORC2 in lipogenesis, adipogenic differentiation, and lipid homeostasis by regulating the activity
of ACLY.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Microrchidia (MORC) family CW-type zinc ﬁnger 2 (MORC2), also
known as ZCWCC1, ZCW3, and KIAA0852, is one of the members of
the MORC protein superfamily [1,2]. The MORC proteins share con-
served features, including a GHKL (gyrase, hsp90, histidine kinase, and
MutL)-ATPase domain [3–5] at the amino-terminus, which functions
in restriction-modiﬁcation systems [2], a CW-type zinc ﬁnger (ZF-CW)
domain, a nuclear localization signal (NLS), and coiled-coil domains at
the carboxy-terminus [6]. According to their ZF-CW domain architec-
tures, MORC proteins have been classiﬁed into two subfamilies;
MORC1 and MORC2 are assigned to subfamily I, whereas MORC3 and
MORC4 belong to subfamily IX [6]. Current evidence suggests that
MORC1 is expressed speciﬁcally in male germ cells and regulates male
gametogenesis [7]. In contrast, MORC3 is ubiquitously expressed in
mammalian cells and induces cellular senescence through regulating
p53 activity [8]. MORC4 is highly expressed in a subset of diffuse large
B-cell lymphoma patients and in B-cell lymphoma cell lines, thus acting
as a potential lymphoma biomarker [9]. Notably, MORC2 is the least
characterized member of the family.c ﬁnger 2; ZF, zincﬁnger; IP, im-
P citrate lyase; IBMX, 3-isobutyl-
dio-immunoprecipitation assay;
lase; FAS, fatty acid synthase;
-3, glycogen synthase kinase-3;
iversity, 2300 Eye Street, N.W.,
ights reserved.The evolutionary, contextual, and gene neighborhood studies
on prokaryotic MORC proteins have predicted a role for eukaryotic
MORCs in chromatin remodeling [2]. In support of this notion, recent
studies pointed out that the members of the MORC protein family are
conserved regulators of heterochromatin condensation and gene silenc-
ing [10]. Consistently, MORC2 has been shown to transcriptionally
repress gene expression [11] and promote chromatin remodeling in
response to DNA damage [12]. However, the biochemical and biological
roles of MORC2 in mammalian cells remain largely unknown.
To uncover new functions of MORC2, we recently conducted an im-
munoprecipitation/mass spectrometry (IP/MS) analysis and identiﬁed
the ATP citrate lyase (ACLY) as one of the MORC2 binding partners.
ACLY is a 121-kDa enzyme that catalyzes the formation of acetyl-
coenzyme A (CoA) and oxaloacetate from citrate and CoA, with the hy-
drolysis of ATP to ADP and phosphate [13]. Cytosolic acetyl-coA is the
requisite building block for several important biosynthetic pathways,
including lipogenesis and cholesterogenesis. Consequently, ACLY is a
key player in the conversion of glucose (exported as citrate from themi-
tochondria) to fatty acids. Acetyl-CoA is also required for acetylation re-
actions that modify proteins, such as histone acetylation [14]. In
addition, ACLY activity is required for growth factor-induced increases
in nutrient metabolism to the regulation of nuclear histone acetylation
and gene expression [15] and is essential for fetal growth and develop-
ment [16].
Alterations of ACLY activity and/or expression have been observed in
different pathological conditions. In this context, it has been document-
ed that ACLY expression is upregulated in different types of cancers,
such as lung, prostate, bladder, breast, liver, stomach and colon cancers
[17–23]. Furthermore, ACLY-dependent production of acetyl-CoA for li-
pogenesis is important for the proliferation of glycolytically converted
Table 1
List of primers used for ampliﬁcation of the ACLY protein regions (R1–R4).
Primer Sequence Regions
ACLY_F1 5′-CGC GAA TTC ATG TCA GCC AAG GCA ATT TCA-3′ R1
ACLY_R1 5′-CGC TCT AGA TCA TTC ATT GAC ACC TCC AAG-3′
ACLY_F2 5′-ACC GAA TTC ATG CTG GCG AAT TAC GGG GAA-3′ R2
ACLY_R2 5′-CGC TCT AGA TCA ACC AGT ATT CCC GAT CTT-3′
ACLY_F3 5′-ACC GAA TTC ATG GGA ATG CTG GAC AAC ATC-3′ R3
ACLY_R3 5′-CGC TCT AGA TCA GGT GAT GGG CAT GCC CGC-3′
ACLY_F4 5′-ACC GAA TTC ATG GAG GTC TTC AAG GAG GAG-3′ R4
ACLY_R4 5′-CGC TCT AGA TTA CAT GCT CAT GTG TTC TGG-3′
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types of tumor cells [17,24,25]. In addition, there is increasing evidence
of the importance of ACLY inmanymetabolic disorders, such as diabetes
[26], pancreatic cell stress and apoptosis [27], obesity [28], hepatic
steatosis [29], and hypocitraturia [30].
Given the critical role of ACLY in many critical biological processes,
and its implication in myriad human diseases, we examined the biolog-
ical consequences of the interaction between MORC2–ACLY identiﬁed
by IP/MS assay. Interestingly, we found that MORC2 interacts with
ACLY speciﬁcally in the cytosol of lipogenic breast cancer cells and reg-
ulates ACLY activity. Changes inMORC2 expression levelswere associat-
ed with changes in the lipogenic capacity of the cells. Moreover, we
demonstrate an essential role of MORC2 in adipocyte differentiation at
the levels of lipogenesis and number of adipocytes. These results open
an interesting new line of research about the control of ACLY activity
as well as lipogenesis, and identify MORC2 as an important component
in lipogenesis, adipocyte differentiation and metabolism.
2. Materials and methods
2.1. Cell culture and treatments
MCF-7, ZR-75-1 and 3T3-L1 cells were obtained from American
Type Culture Collection (Manassas, VA). MCF-7 and ZR-75-1 cells were
cultured in Dulbecco's Modiﬁed Eagle's Medium/F-12 (DMEM/F-12)
(Atlanta Biologicals Inc., GA), supplemented with 10% fetal bovine
serum, and 3T3-L1 cells were cultured in Dulbecco's Modiﬁed Eagle's
Medium (DMEM) supplemented with 10% calf bovine serum. All media
were additionally supplementedwith 1× antibiotic–antimycotic solution
(Life Technologies, Grand Island, NY). All cell cultures were maintained
in a humidiﬁed 5% CO2 atmosphere at 37 °C. For those experiments in
which 3T3-L1 cellswere treatedwith the adipogenic differentiation cock-
tail in the presence of actinomycin D or cycloheximide, cells were ﬁrst
pre-incubated with 10 μg/ml cycloheximide or 0.5 μg/ml actinomycin
D. Subsequently, cells were washed with PBS and then placed into a
medium containing insulin, 3-isobutyl-1-methylxanthine (IBMX),
dexamethasone and either cycloheximide or actinomycin D at the same
working concentration for 24 h. After incubation, the cells were collected
and lysed for Western blot analysis.
2.2. Antibodies and reagents
Sources of antibodieswere as follows: rabbit anti-MORC2 (for detec-
tion of human MORC2) and anti-T7 were purchased from Bethyl Labo-
ratories (Montgomery, TX); goat anti-MORC2 (for detection of mouse
MORC2), rabbit anti-cyclin D1, anti-progesterone receptor (PR) and
anti-HDAC2 antibodies were purchased from Santa Cruz Biotechnol-
ogies (Santa Cruz, CA); rabbit anti-phospho-ACLY, anti-ACLY, anti-
phospho-ACC, anti-ACC, and anti-FASwere obtained fromCell Signaling
Technology (Danvers, MA); rabbit anti-AP2 was obtained from Abcam
(Cambridge, MA); and mouse anti-α-tubulin, anti-vinculin, anti-actin,
and normal rabbit IgG were obtained from Sigma-Aldrich (St. Louis,
MO). All primary antibodies were used as according to manufacturer's
instructions. Horseradish peroxidase-conjugated secondary antibodies
were from GE Healthcare (Piscataway, NJ), and enhanced chemilumi-
nescence (ECL) reagentswere fromAmershamBiosciences (Piscataway,
NJ). Potassium citrate, ATP, CoA, malate dehydrogenase, nicotinamide
adenine dinucleotide (NADH), MgCl2, Tris–HCl, DTT, actinomycin D,
cycloheximide, insulin, and IBMXwere from Sigma-Aldrich. Dexameth-
asone was purchased from G Biosciences (St. Louis, MO).
2.3. Expression vectors, recombinant proteins, siRNAs, and transfections
The expression vector encoding ACLY was generously provided by
Kathryn E. Wellen (University of Pennsylvania, Philadelphia, PA) and
has been previously described [15]. To generate various deletion ACLYexpression vectors, the cDNA fragments corresponding to amino acid
residues 1–300 (region 1), 300–630 (region 2), 630–850 (region 3),
and 850–1092 (region 4) were ampliﬁed by PCR using the primers
listed in Table 1. Each fragment was ligated into the EcoRI-XbaI sites of
pEF6/V5-HIS vector (Invitrogen, Carlsbad, CA). In vitro translation
was performed using the TNT®Quick Coupled Transcription/Translation
Systems (Promega, Madison, WI). T7-MORC2, glutathione-S-transferase
(GST)-MORC2 N-terminal (63–718 amino acids) and C-terminal (718–
1032 amino acids) expression plasmids have been previously described
[12]. All GST recombinant proteins were expressed in Escherichia coli
strain BL21 (DE3) (Stratagene, La Jolla, CA) and subsequently puriﬁed
using the Glutathione Sepharose 4B batch method (GE Healthcare,
Piscataway, NJ). Plasmid transfections were carried out using FuGENE
HD Transfection Reagent (Roche Applied Science, Indianapolis, IN) ac-
cording to manufacturer's instructions. Speciﬁc siRNAs targeting mouse
or human MORC2 or control siRNAs were obtained from Thermo Fisher
Scientiﬁc (Rockville, MD). The transfection of siRNA was performed
twice at 24-h intervals with Oligofectamine™ reagent (Invitrogen) ac-
cording to the manufacturer's protocol.
2.4. Quantitative real time PCR (qPCR)
Total RNA was isolated from cultured cells using TRIzol reagent
(Invitrogen) according to the manufacturer's protocol, and 2 μg of ex-
tracted RNA was converted to cDNA using the SuperScript™ III First-
Strand Synthesis System for RT-PCR (Invitrogen). The resultant cDNA
was subjected to qPCR by using the iQTM SYBR® Green Supermix
(Bio-Rad Laboratories, Hercules, CA) on an iCycler iQ™ Real-Time PCR
Detection System (Bio-Rad Laboratories). The values for speciﬁc genes
were normalized to human or mouse actin housekeeping controls.
Mean values are displayed ± standard deviations. The primers used
for qPCR are listed in Table 2. All qPCR primers were synthesized in
Sigma-Aldrich.
2.5. Western blot and immunoprecipitation
Protein extracts were prepared by lysing the cells in radio-
immunoprecipitation assay (RIPA) buffer containing 50 mM Tris–HCl,
pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM EDTA, 1× protease inhibitor cocktail (Roche Applied Science),
and 1× phosphatase inhibitor cocktail I and II (Sigma-Aldrich). Nuclear
and cytoplasmic extracts were prepared as described previously [31].
Protein concentrations were determined using Bio-Rad DC Protein
Assay reagents (Bio-Rad Laboratories). Cell extracts were then resolved
by SDS-PAGE, transferred to nitrocellulose membranes, and incubated
with the indicated antibodies. Detections were performed using the
ECL reagents. For immunoprecipitation (IP) analysis, total 1 mg of pro-
teinmaterials was incubatedwith 1 μg of primary antibody overnight at
4 °C on a rocket platform, followed by incubationwith total 50 μl of pro-
tein A/G PLUS-agarose (Santa Cruz Biotechnology) or Trueblot IP beads
(eBioscience, San Diego, CA) for 2 h at 4 °C. The immunoprecipitates
were collected by centrifugation in a microcentrifuge at 6000 rpm for
5 min. The supernatant was discarded, whereupon the pellet was
washed with Nonidet P-40 (NP40) buffer (50 mM Tris–HCl, pH 8.0,
Table 2
qPCR primers used in this study.
Primer Sequence
q_hMORC2_F 5′-CCC AAG CAG ACC TGA AGA AA-3′
q_hMORC2_R 5′-TTC CTG ATC ACA GCA GGT AAA G-3′
q _hACTIN_F 5′-TCC CTG GAG AAG AGC TAC GA-3′
q_hACTIN_R 5′-GTA CTT GCG CTC AGG AGG AG-3′
q_hAP2_F 5′-ACT GGG CCA GGA ATT TGA CGA AGT-3′
q_hAP2_R 5′-TCT CGT GGA AGT GAC GCC TTT CAT-3′
q_mMORC2_F 5′-AGG AGC CAT TTC CTG AGT CAA CCA-3′
q_mMORC2_R 5′-ACA CCT GCA CAC CCT GAG AAT CTT-3′
q_mACTIN_F 5′-TCC CTG GAG AAG AGC TAT GA-3′
q_mACTIN_R 5′-GTA CTT GCG CTC AGG AGG AG-3′
q_mAP2_F 5′-AGT CAC ATG GTC CAG GGC ATC TT-3′
q_mAP2_R 5′-AAC CTT CGA GGA GGA GCT GTC T-3′
q_mPPARg_F 5′-TGA AGC CCA TCG AGG ACA TC-3′
q_mPPARg_R 5′-TGA CGA TCT GCC TGA GGT CTG-3′
q_mACLY_F 5′-TGG AGG TGT CAA TGA ACT GGC GAA-3′
q_mACLY_R 5′-ATC TTG CCT TCT GGG TGC TTC TCT-3′
q_m_FAS_F 5′-TAT CCT GCT GTC CAA CCT CAG CAA-3′
q_m_FAS_R 5′-TCA CGA GGT CAT GCT TTA GCA CCT-3′
q_m_ACC1_F 5′-ATG TTC CAT GTG GCC TGG GTA GAT-3′
q_m_ACC1_R 5′-TCA CAG TGG ACA GAA TTG AGG GCA-3′
q_mCEBPa_F 5′-GCT GAG TTG ACC AGT GAC A-3′
q_mCEBPa_R 5′-AAA CCA TCC TCT GGG TCT CC-3′
q_mCEBPb_F 5′-TGA TGC AAT CCG GAT CAA ACG TGG-3′
q_mCEBPb_R 5′-TTT AAG TGA TTA CTC AGG GCC CGG C-3′
q_hHMGCR-F 5′-TGA AGG GTT CGC AGT GAT AAA-3′
q_hMGCR-R 5′-CCT GGA CTG GAA ACG GAT ATA AA-3′
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EDTA), with protease inhibitors for three to ﬁve times and then dis-
solved in a sample buffer for SDS-PAGE. The protein bands in theWest-
ern blot were quantiﬁed using ImageJ software.
2.6. GST pull-down assays
The GST pull-down assays were performed by incubating equal
amounts of GST or GST fusion protein immobilized to glutathione-
sepharose beads with in-vitro translated 35S-labeled protein in a
400 μl reaction volume. The mixtures were incubated for 2 h at 4 °C
and washed three to six times with NP40 lysis buffer. Bound proteins
were eluted with 2× SDS buffer, separated by SDS-PAGE and visualized
by autoradiography. The transferred protein on the blot was visualized
using Ponceau S staining.
2.7. ACLY activity enzymatic assays
ACLY enzymatic activity was assayed by the coupled malate dehy-
drogenase (MDH) method [32], which monitors the decreased in
NADH levels by the oxidation of oxaloacetate byMDH. Cytosolic lysates
extracted from the different cell samples were subjected to the assay.
The standard assay mixture consisted of 50 mM Tris–HCL (pH 8.0),
10 mM MgCl2, 1.9 mM DTT, 0.15 mM NADH, 0.07 mM CoA, 1 mM
ATP, 2 mM potassium citrate, and 3.3 U/ml malate dehydrogenase. As-
says were conducted at 37 °C in a temperature-controlled Synergy H1
HybridMicroplate Reader (Biotek,Winooski, VT). Change in absorbance
in the presence of exogenousATPwas subtracted from change in the ab-
sence of ATP andwas normalized to protein concentration to determine
the speciﬁc ACLY activity.
2.8. Adipocyte differentiation and Oil Red O staining
3T3-L1 cells were cultured to conﬂuence in DMEM supplemented
with 10% calf bovine serum. At 2 days post-conﬂuence (designated
day 0), cells were induced to differentiate with DMEM supplemented
with 10% fetal bovine serum, 1 μM dexamethasone (G-Biosciences),
0.5 mM isobutylmethylxanthine IBMX (Sigma-Aldrich), and 1 μg/ml in-
sulin (Sigma-Aldrich). After 48 h, themedia were replaced with DMEMsupplemented with 10% FBS and 1 μg/ml insulin. Cells were provided
with fresh DMEM 10% FBS plus 1 μg/ml insulin every 48 h. For
adipogenic assays of cells treated with siMORC2, cells were transfected
with the siRNA two times, and then maintained until reaching conﬂu-
ence, according to the protocol described in Section 2.3. 3T3-L1 adipo-
cytes were ﬁxed with 3.7% formaldehyde and washed with PBS. Cells
were stained with Oil Red O working solution (six parts of saturated
Oil Red O-isopropanol solution (Sigma-Aldrich) and four parts of
water) for 15 min at room temperature and then exhaustively rinsed
with water. Stained or non-stained adipocytes were visualized with an
Olympus IX71 microscope. Representative images were acquired with
an Olympus DP72 camera using DP2-BSW software. These assays
were repeated at least three times.
3. Results
3.1. Identiﬁcation of ACLY as a MORC2-interacting partner
Our recent immunoprecipitation/mass spectrometry (IP/MS) study
identiﬁed ACLY as a potential MORC2-interacting protein in HeLa cells
(Kumar R., unpublished data). In light of the functional importance of
ACLY in metabolism [13] and acetylation reactions and protein modiﬁ-
cations [15], we attempted to further investigate the functional implica-
tions of the MORC2–ACLY interaction. To this aim, we next conﬁrmed
that endogenous MORC2 associates with the endogenous ACLY in
HeLa cells using a sequential IP/Western blot analysis (Fig. 1A). Further-
more, we found that in vitro-translated ACLY was able to directly inter-
act with GST-MORC2, preferentially to the amino-terminal half of the
GST-MORC2 protein (amino acids 63–718) (Fig. 1B). These results dem-
onstrate that ACLY interacts with MORC2 in vitro and in vivo.
3.2. ACLY and MORC2 speciﬁcally interact in the cytosol of lipogenic breast
cancer cells
Because of the low capacity of de novo lipogenesis of HeLa cells [33]
and the prominent function of ACLY in lipogenesis [13], we decided to
employ MCF-7 cells, an epithelial breast cancer cell line with high
lipogenic ability [34], for further functional studies. Emerging evidence
suggests that MORC2 is predominantly localized in the nuclear com-
partment [12] (Fig. 1C) and ACLY is mainly a cytosolic enzyme [13]
(Fig. 1C). We localized the interaction between MORC2 and ACLY by
IP of the endogenous MORC2 from both nuclear and cytosolic MCF-7
cell lysates, followed byWestern blot analysis for ACLY protein expres-
sion. As shown in Fig. 1D, ACLY co-immunoprecipitated with the
MORC2 out of the MCF-7 cytosolic fraction, but not out of the nuclear
fraction. These results suggest that, at least under our experimental con-
ditions, the interaction betweenMORC2 and ACLY occurs speciﬁcally in
the cytosol of MCF-7 cells.
3.3. MORC2 speciﬁcally binds to a region of ACLY important for
its activation
To understand the consequences of the interaction betweenMORC2
and ACLY, we next mapped the interacting region between both pro-
teins. The ACLY protein contains four structural domains [35], named
here as domains I–IV relative to the amino-terminus (Fig. 2A). Domain
I adopts an ATP-grasp fold [36] and binds nucleotides [37]. Domain II
binds CoA, and domains III and IV share similarity to ligase coA and cit-
rate synthase, respectively [35]. Thus, the ACLY full length protein was
subdivided into four regions (R1 to R4), each one containing one of
the domains described above, for cloning and subsequent in vitro trans-
lation. GST pull-down assays were carried out using each one of these
in vitro translated peptides and GST-MORC2 proteins (N-terminal and
C-terminal halves). As shown in Fig. 2B, only the region 2 of ACLY
(R2) was able to interact with GST-MORC2. Interestingly, we noticed
that, similar to full-length ACLY protein (Fig. 1B), this region of ACLY
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Fig. 1.MORC2 interacts with ACLY. A. Protein extracts fromHeLa cells were immunoprecipitatedwith an anti-MORC2 antibody, followed byWestern blotting using the indicated antibod-
ies. B. In vitro transcribed-translated ACLY protein (35S-labeled) was incubated with GST-MORC2 N-terminal or C-terminal truncation constructs. Bound proteins were separated and an-
alyzed by SDS-PAGE and autoradiography. The lower panel shows a Ponceau S-stained blot containing either GST-MORC2 N-terminal or GST-MORC2 C-terminal and GST. The asterisk (*)
denotes thepresence of the GST, GST-MORC2N-terminal andGST-MORC2C-terminal fusion proteins. C. Nuclear (NL) and cytosolic (CL) protein lysates fromMCF-7 cellswere subjected to
Western blot analysis of MORC2 and ACLY. HDAC2 and paxillin protein expression was used as nuclear and cytosolic markers, respectively. D. The same lysates assayed in C were
immunoprecipitated using an anti-MORC2 antibody, followed byWestern blot analysis using the indicated antibodies. IP: immunoprecipitation.
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worth mentioning that region 2 of ACLY protein (300–630 aa) contains
the domain II that binds CoA. Furthermore, region 2 contains several
residues that can be phosphorylated and are important for ACLY activa-
tion [38–40]. These results show thatMORC2 andACLY interact directly,
and this interaction requires the Co-A-binding domain II of ACLY.
3.4. MORC2 expression levels affect ACLY activity
Thr446, Ser450 and Ser454 residues of mouse ACLY were shown to
be phosphorylated in vitro [41] and indirectly reﬂect the activation sta-
tus of ACLY [42]. This ﬁnding, taken together with the results presented
above, suggests that MORC2 may affect ACLY activity by selectively
binding to a region of ACLY containing several phosphorylatable resi-
dues. To test this hypothesis, we examined the effect of MORC2 expres-
sion on the levels of ACLY phosphorylation at Ser455 (human
homologue residue to mouse Ser454) in two lipogenic breast cancer
cell lines: MCF-7 and ZR-75-1. Interestingly, we found that induced ex-
pression ofMORC2 resulted in a signiﬁcant increase in the phosphoryla-
tion level of ACLY in MCF-7 (Fig. 3A) and ZR-75-1 (Fig. S1A). In
agreement with previous data [17], the increase in ACLY phosphoryla-
tion contributed to its protein stabilization, and higher levels of total
ACLY were also observed when MORC2 was overexpressed (Fig. 3A).
In contrast, depletion of the endogenous MORC2 by a speciﬁc siRNA in
MCF-7 cells resulted in a signiﬁcant reduction of ACLY phosphorylation
(Fig. 3B).To further conﬁrm these results, we conducted kinetic assays to de-
termine the activation level of cytosolic ACLY under the conditions of
overexpression or knockdown of MORC2. For this purpose, the enzy-
matic activity of ACLY was assayed by the malate-dehydrogenase
(MDH) method [43]. This assay monitors the decrease in NADH levels
at 340 nm by the MDH oxidation of oxaloacetate (resulting from ACLY
activity) [43]. As shown in Fig. 3C, following MORC2 overexpression,
the activity of ACLY was clearly induced in both MCF-7 (Fig. 3C) and
ZR-75-1 (Fig. S1B) cytosolic lysates. In addition, ACLY activity was dra-
matically reduced in the cytosol of MCF-7 cells after the speciﬁc knock-
down of MORC2 by siRNA transfection (Fig. 3C). Altogether, these
results suggest that MORC2 regulates ACLY activity.
3.5. MORC2 is essential for fatty acid and mevalonate pathways
ACLY is the major source of cytosolic acetyl-CoA for lipogenesis in
mammalian cells [13]. Lipogenesis comprises multiple sequential steps
governed by several enzymes, including ACLY, acetyl-CoA carboxylase
(ACC) and fatty acid synthase (FAS) [31]. ACLY catalyzes the ﬁrst step,
consisting in the conversion of cytosolic citrate into acetyl-CoA and oxa-
loacetate, and supplying the essential metabolites for the pathway. Next,
ACC catalyzes the carboxylation of acetyl-CoA to produce malonyl-CoA,
and FAS subsequently condenses acetyl-CoA andmalonyl-CoA to gener-
ate long chain fatty acids.
Given our ﬁndings that MORC2 regulates ACLY activity (Figs. 3 and
S1), we hypothesized that MORC2 can affect the levels of available
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Fig. 2.MORC2 interacts with a region of ACLY important for its activation. A. Schematic representation of the ACLY protein, showing the domains of the protein (I–IV) and the different
regions (R1–R4), in which the full length protein was subdivided for in vitro translation. I: ATP-grasp fold domain. II: Coenzyme A (CoA)-binding domain. III: ligase coA-like domain.
IV: citrate synthase-like domain. B. In vitro transcribed-translated (35S-labeled) ACLY protein regions (R1–R4) or full-length ACLY (FL) were incubated with GST-MORC2 N-terminal or
GST-MORC2-C-terminal half constructs, or GST. Bound proteins were separated and analyzed by SDS-PAGE and autoradiography. The lower panels are the Ponceau S-stained blots show-
ing either GST-MORC2 N-terminal or GST-MORC2 C-terminal and GST. The asterisk (*) denotes the presence of the GST, GST-MORC2 N-terminal and GST-MORC2 C-terminal fusion
proteins.
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cated in the regulation of the lipogenic pathway. Indeed, we found that
MORC2 depletion in MCF-7 cells was followed by a marked downregu-
lation in the protein expression levels of ACC and FAS (Fig. 4A), suggest-
ing that MORC2 is essential for the lipogenic process. In contrast,
induced expression of MORC2 increased the phosphorylation and pro-
tein levels of ACC, as well as FAS protein levels in both MCF-7 (Fig. 4C)
and ZR-75-1 cells (Fig. S2A). Furthermore, the level of aP2 protein, a
marker of adipocytes [44], was induced in cells overexpressing
MORC2 (Fig. 4C), but was downregulated following depletion of the en-
dogenousMORC2by a speciﬁc siRNA inMCF-7 cells (Fig. 4B). Collective-
ly, these results suggest that MORC2 is required for the optimum
lipogenic activity of these enzymes and is involved in intracellular
lipid accumulation.
Because the acetyl CoA resulting from ACLY activity is also an essen-
tial substrate for the mevalonate pathway [45], we studied the effect of
MORC2 on this pathway. The ﬁrst and rate-limiting step in the
mevalonate pathway is regulated by the enzyme 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGCR) [46], which converts the acetyl coA
into mevalonate, which can be later transformed into cholesterol or
isoprenoids. As shown in Figs. 4D and S2B,we observed thatMORC2 ex-
pression is essential for the mevalonate pathway, and the depletion of
the endogenous MORC2 by a speciﬁc siRNA in both MCF-7 (Fig. 4D)
and ZR-75-1 (Fig. S2B) breast cancer cells was associated with a de-
creased expression of HMGCR mRNA. Altogether, these data suggest
that MORC2, by affecting ACLY activity, regulates the levels of available
acetyl CoA which can be used either for the fatty acid synthesis or the
mevalonate pathways.
3.6. MORC2 is induced and essentially required for 3T3-L1 adipogenesis
Lipogenesis is required for the execution of de novo adipogenesis,
which includes both lipogenic and adipogenic gene expression. Adipo-
genesis, also called adipocyte differentiation, is a complex process accom-
panied by coordinated changes in morphology, hormone sensitivity, andgene expression that take place during the conversion of preadipocytes
into fully matured adipocytes, which possess the full complement of en-
zymes and regulatory proteins required to execute both de novo lipogen-
esis and lipolysis [47]. Following these observations, we next examined
whether MORC2 regulates adipocyte differentiation using 3T3-L1
mouse preadipocytic cells as an experimental model. Under a standard
protocol of adipogenic differentiation [32], these cells are able to trans-
form from ﬁbroblast-like preadipocyte cells into fully mature adipocytes.
We ﬁrst analyzed MORC2 mRNA and protein expression levels during
3T3-L1 adipocyte differentiation, and found that the levels of MORC2
mRNA (Fig. 5A) as well as protein (Fig. 5B) were signiﬁcantly increased
in differentiated 3T3-L1 cells as compared with non-differentiated cells,
suggesting that MORC2 may play a role in 3T3-L1 adipogenesis. To con-
ﬁrm these ﬁndings, we next selectively knocked down the endogenous
MORC2 in 3T3-L1 cells using a speciﬁc MORC2 siRNA, and then induced
these cells to differentiate. At day 0 of differentiation, just when the
adipogenic cocktail was added to the cells, we conﬁrmed the downregu-
lation of MORC2 expression in MORC2 siRNA-3T3-L1 transfected cells
(3T3-L1 siMORC2) compared with control siRNA-transfected cells (3T3-
L1 siC) (Fig. 5D). We found that 3T3-L1 siMORC2 cells also showed de-
creased expression levels of several adipocyte speciﬁc genes (aP2,
PPARγ, C/EBPα, C/EBPβ) and various lipogenic genes (such as ACLY, ACC
and FAS) (Fig. 5D). Furthermore, 6 days after the induction of the
adipogenic differentiation, the adipogenic conversion of 3T3-L1 siMORC2
cells was clearly compromisedwhen compared to that of 3T3-L1 siC cells
(Fig. 5E and F). As shown in Fig. 5E, the expression levels of different ad-
ipocyte speciﬁc genes, such as aP2, PPARγ, C/EBPα, and C/EBPβ (Fig. 5E);
aswell as that for lipogenic genes ACLY, ACC and FAS (Fig. 5F)were highly
inhibited indifferentiated 3T3-L1 siMORC2 cells, comparedwithdifferen-
tiated control cells (3T3-L1 siC). In addition, the number of adipocytes
stained with Oil Red O was also signiﬁcantly reduced in the absence of
MORC2 (Fig. 5G). Taken together, these results suggest that MORC2 is
required for the full completion of the adipogenic process at the level
of lipogenesis, number of adipocytes and adipocyte speciﬁc gene
expression.
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MORC2 appears to regulate adipocyte differentiation (Fig. 5) and
lipogenesis (Figs. 4 and 5) in the cytosol of the cells. However, since
MORC2 is mainly localized in the nuclei [12], we next examined
whether the adipogenic signal can induce MORC2 cytosolic expres-
sion or re-localization. As shown in Fig. 6A, we found that the treat-
ment of 3T3-L1 cells for 24 h with the adipogenic cocktail containing
insulin, IBMX and dexamethasone was able to induce an increase in
MORC2 protein levels in total cell lysates, conﬁrming an overall in-
crease in MORC2 protein after 3T3-L1 differentiation (Fig. 5A and
B). In the fractionated cells, we detected an induction of MORC2 pro-
tein levels in cytosolic fraction of 3T3-L1 cells, but expression in nu-
clear fraction did not change (Fig. 6A), suggesting that the signals of
adipogenic differentiation promote an induction of MORC2 cytosolic
protein levels, rather than a re-localization from the nucleus to cyto-
sol. To further validate the hypothesis that adipogenic stimulation
induces cytosolic expression of MORC2, we next analyzed thelocalization and protein expression of MORC2 in 3T3-L1 cells after
24 h of treatment with the adipogenic cocktail in the presence of ac-
tinomycin D or cycloheximide. As expected, the addition of actino-
mycin D or cycloheximide to the differentiation cocktail suppressed
the induction of MORC2 protein in total lysates and consequently
in cytosolic lysates (Fig. 6B).
Themammary gland is an excellent system in which to study differ-
entiation. The lactating mammary gland of many species synthesizes
medium-chain fatty acids esteriﬁed as milk triglycerides. At late stages
of pregnancy (days 15 to 18)mammary gland undergoes intense differ-
entiation [48]. During this period there is increased lipogenesis and the
ability to synthesize themedium-chain fatty acids, characteristics of the
milk [48]. We analyzed the levels of MORC2 protein in mammary gland
from virgin, pregnant and lactating mice, and found an increase in
MORC2 protein expression alongwith differentiation (Fig. 6C). Interest-
ingly, the induction of MORC2was highly correlated to the induction of
ACLY activity during pregnancy (day 18) (Fig. 6C), demonstrating the
role of MORC2 in differentiation and lipogenesis.
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Here, we provide the ﬁrst evidence that MORC2, a previously recog-
nized nuclear protein, functions in the cytosol through an interaction
with ACLY. This interaction is required for lipogenesis and adipogenesis,
which uncovers a new cytosolic role for MORC2 in addition to its nucle-
ar functions in gene expression and chromatin remodeling in response
to DNA damage signaling [11,12] (Fig. 7).
The original implication of MORC2 in lipogenesis was derived from
the biology of ACLY and the cytosolic localization of the MORC2–ACLY
interaction. Although ACLY is mainly a cytosolic protein, emerging evi-
dence pointed out the localization of ACLY in the nucleus of different
mammalian cells, such as human glioblastoma cells, mouse embryonic
ﬁbroblasts, murine pro-B-cell lymphoid cells and human colon carcino-
ma cells [15]. Both nuclear and cytosolic ACLY are implicated in the for-
mation of acetyl-CoA, but this metabolite is employed for different
purposes depending on the localization of ACLY. Cytosolic acetyl-CoA
is mainly used for lipogenic and/or cholesterogenic pathways [13],
while nuclear acetyl-CoA is used for histone acetylation and changes
in gene expression associated to metabolism [15]. Interestingly, we
found that the interaction of MORC2 with ACLY was naturally and spe-
ciﬁcally occurring in the cytosol of MCF-7 cells, suggesting that MORC2
may play an important role in fatty acid metabolism in the cytosol of
cells.
Indeed, this emerging role of MORC2 in fatty acid metabolism was
ﬁrmly supported by several lines of evidence. First, we found that
MORC2 regulates ACLY phosphorylation and activation. The in vitrointeraction between these two proteins was mapped in a region of
ACLY from amino acids 300 to 630, which contain a stretch of residues
that are good candidates for phosphorylation and are important for
ACLY activation [38–40]. Three regulatory phosphorylation sites in
mouseACLY have been identiﬁed [39] that are distinct from the catalytic
auto phosphorylation site (His 760), including Thr 446 and Ser 450,
which are phosphorylated by glycogen synthase kinase-3 (GSK-3)
[39,49], and Ser 454, which is phosphorylated by cAMP-dependent pro-
tein kinase (PKA) [38,50], or by an “insulin-stimulated kinase(s)” [51].
In this study, Western blot analysis and enzymatic activity assays con-
ﬁrmed that MORC2 regulates the phosphorylation levels of ACLY on
Ser 454 residue and its activation status [42]. Since the interaction be-
tween MORC2 and ACLY occurs in a region of ACLY that is susceptible
of phosphorylation, we speculate that MORC2, which lacks any kinase
activity, may play a protective role against the dephosphorylation of
ACLY protein, which consequently would lead to the observed positive
net effect of MORC2 in ACLY phosphorylation and activation. Future
studies are needed to explore these and other possibilities including
the nature and/or effect of the possible responsible kinase.
Second, our results show thatMORC2 regulates the levels of ACC and
FAS enzymes. ACLY-mediated cytosolic production of acetyl-coA is re-
quired for the subsequent steps of fatty acid biosynthesis, which in-
cludes two additional to convert the cytosolic acetyl-coA ﬁrst into
malonyl-coA and later in fatty acids. These two steps are governed by
ACC and FAS enzymes. Thus, our results suggest that MORC2 may play
an important role in the entire lipogenic pathway. Because ACLY is
located upstream of the other lipogenic enzymes (ACC and FAS), the
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tion may provide a potential advantage over therapeutic strategies
targeting other lipogenic enzymes. It is known that small changes in
the rates of enzymes at the beginning of a biochemical pathway com-
posed of many enzymes may produce signiﬁcant changes in the rate
of production of the end product [42], and we demonstrate an exampleof such a pathway here. Additional evidence supporting the role of
MORC2 in the regulation of ACLY-mediated cytosolic production of
acetyl-coA is derived based on the preliminary analysis of HMGCR, the
ﬁrst and rate-limiting enzyme of the mevalonate pathway [46]. Al-
though further experiments need to be conducted, our results suggest
that MORC2 may be implicated in this pathway.
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involved in the accumulation of fatty acids. The results show a direct re-
lationship betweenMORC2 expression and aP2 expression levels. aP2 is
a common marker of adipocytes [44], and our results suggest that
MORC2 is a positive regulator for its abundance within the cytosol.
Fourth, our ﬁndings show that MORC2 is involved in adipocyte dif-
ferentiation. Like other inducers of adipogenesis, such as C/EBP proteins
and PPARγ [52], we found that the expression of MORC2 was induced
during 3T3-L1 adipocyte differentiation. Furthermore, we revealed
thatMORC2was required for 3T3-L1 adipogenesis involving lipogenesis
and the accumulation of Oil Red O-stained lipid droplets, as well as the
expression of several adipocyte-speciﬁc markers, including aP2, PPARγ,
C/EBPα and C/EBPβ. Although further experiments are needed, the data
presented here suggest that MORC2 affects ACLY activity and thus con-
trols the lipogenic pathway from an early step in adipocyte differentia-
tion. However, there are additional plausible explanations. For example,
theremay be an additional role forMORC2 in the transcriptional control
of adipogenesis genes. The fact that MORC2 has been highly involved in
the regulation of gene transcription [11], and our own results showing
that knockdown of MORC2 inhibited the expression of several tran-
scriptional regulators of adipogenesis (PPARγ, C/EBPα, C/EBPβ) support
this hypothesis. Therefore, our data do not exclude the possibility that
MORC2affects adipocyte differentiation in twoways;ﬁrst by the control
of lipogenesis in the cytosol and second through adipocyte-speciﬁc gene
expression. These two processes are often undistinguished in adipocyte
differentiation. However, it is remarkable to note that, while lipogenesis
actively occurs in several tissues, including fat and liver tissues, adipo-
genesis is restricted to fat cells. Furthermore, adipocyte-speciﬁc gene
expression is required for fat cell-speciﬁc functions, such as the synthe-
sis of adipocytokines. These facts are of high importance, because it is
well known that adipocytes and particularly, adipocytokines play an es-
sential role in regulating the whole-body energy metabolism [53]. In
this regard, MORC2 is positioned as a key player in energy (lipid) ho-
meostasis and metabolism, implying novel functions for a member ofthis protein family. In addition, the positive role ofMORC2 in lipogenesis
was further conﬁrmed in mammary gland development, with its in-
duced expression coincident with the increment of lipogenesis and
ACLY activation in late pregnancy, around days 15–18.
Lipogenesis is activated during cell growth and proliferation [54,55]
and one of the most important metabolic hallmarks of cancer is in-
creased de novo lipid synthesis, because of the high proliferation rate
and the consequent demand for energy and macromolecules [56]. Fur-
thermore, ACLY appears to be upregulated in lung, prostate, bladder,
breast, liver, stomach, and colon tumors [17–23]. Concomitantly, ACLY
inhibition may result in growth arrest in tumor cells, both in vitro and
in vivo [17,24]. In the present study, we have observed that MORC2
upregulates ACLY phosphorylation and activity in two different breast
cancer cell lines, MCF-7 and ZR-75-1. In this regard, MORC2, or the com-
plex including MORC2 and ACLY, may provide an interesting novel tar-
get not only for ACLY-mediated lipogenesis, but also for ACLY-mediated
tumorigenesis.
In summary, we report a novel interaction between ACLY and
MORC2 and present evidence about the role of MORC2 in the regulation
of ACLY activities in lipogenesis and adipocyte differentiation. Our re-
sults showMORC2 localized in the cytosol as a key player in lipidmetab-
olism and homeostasis. These novel results suggest that targeting the
MORC2–ACLY interaction may represent a new avenue for controlling
many important metabolic pathways and their associated human
diseases.
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